Answers are grounded in this paper and cite their sources.
Objective To examine whether baseline C-reactive protein (CRP) is associated with illness severity and with antipsychotic treatment response in Moroccan patients with schizophrenia. Methods In a single-centre prospective observational cohort (Casablanca), 85 adults with DSM-5 schizophrenia in an acute phase were assessed at baseline (W0) and followed at week 6 (W6), week 12 (W12, primary endpoint) and week 24 (W24). A single baseline CRP measurement (available in 82 patients) was related to PANSS and CGI-S scores. Response was defined as a ≥ 20% reduction in PANSS total score after subtraction of the 30 minimum points, with ≥ 50% as a stricter threshold. Because non-responders were few, the multivariable logistic regression (Firth penalized likelihood, adjusted for clinical and treatment covariates) was considered exploratory and complemented by sensitivity analyses, including the area under the ROC curve (AUC) and a continuous outcome. Results CRP was frequently elevated (median 7.1 mg/L); 62/82 (75.6%) patients had CRP > 3 mg/L. Baseline CRP correlated moderately with PANSS total score (Spearman ρ = 0.39, p < 0.001). Mean PANSS total decreased from 71.6 at W0 to 61.0 at W6 and 50.6 at W12; 65/77 (84.4%) completers met the ≥ 20% criterion and 52/77 (67.5%) the ≥ 50% criterion at W12. With only eight non-responders in the adjusted model, the estimate for CRP > 3 mg/L was very imprecise (adjusted OR 0.74, 95% CI 0.07–4.13). CRP did not discriminate W12 non-responders (AUC 0.49, 95% CI 0.34–0.64) and was not associated with percentage improvement (− 0.2 points per doubling of CRP, 95% CI − 4.8 to 4.5). At W24, 64/67 (95.5%) completers met the ≥ 20% criterion, with no significant difference between CRP strata. Conclusions In this observational cohort, a single baseline CRP measurement was moderately correlated with acute severity. No association with treatment response was found, but with so few non-responders a predictive value can be neither confirmed nor excluded. An association with severity does not establish CRP as a clinically useful biomarker; adequately powered studies with repeated CRP measurements are needed.
No takes yet. Share an insight, caveat, or question.
Falah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: